This website is intended for UK healthcare professionals only
User log in




Trial log in
  

Simon, age 62, has had type 2 diabetes for 6 months; it was diagnosed following an admission to hospital with chest pain, which was subsequently diagnosed as angina. He has a BMI of 42kg/m2, and although he has managed to lose some wieight, this has plateaued. His latest HbA1c is 59mmol/mol and he is treated with metformin 2g daily. He has normal renal function. Which class of drugs would offer Simon improvement in his glycaemic control, whilst supporting him to lose weight given that he has established cardiovascular disease. 

(Please select 1 option)

A sulfonylurea
A GLP-1 RA or SGLT2 inhibitor
A DPP-4 inhibitor
Pioglitazone

0 of 4 questions answered (0%)

You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI's products, services and events.

Click here for Trajenta (linagliptin) Prescribing Information: Great Britain | Northern Ireland

Click here for Jardiance (empagliflozin) Prescribing Information: Great Britain | Northern Ireland

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).